Article révisé par les pairs
Titre:
  • Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2
Auteur:Gnant, Michael; Baselga, José; Rugo, Hope; Noguchi, Shinzaburo; Burris, Howard H.A.; Piccart-Gebhart, Martine; Hortobagyi, Gabriel N.; Eakle, Janice; Hart, Lowell L.L.; Mukai, Hirofumi; Iwata, Hiroji; Geberth, Matthias; Hadji, Peyman; El-Hashimy, Mona; Rao, Shantha; Taran, Tetiana; Sahmoud, Tarek; Lebwohl, David; Campone, Mario; Pritchard, Kathleen
Informations sur la publication:Journal of the National Cancer Institute, 105, 9, page (654-663)
Statut de publication:Publié, 2013-05
Sujet CREF:Cancérologie
MeSH keywords:Aged
Alkaline Phosphatase -- blood
Androstadienes -- administration & dosage
Antineoplastic Agents -- pharmacology -- therapeutic use
Aromatase Inhibitors -- administration & dosage
Bone Density -- drug effects
Bone Density Conservation Agents -- pharmacology -- therapeutic use
Bone Neoplasms -- blood -- metabolism -- prevention & control -- secondary
Bone Remodeling -- drug effects
Bone Resorption -- drug therapy -- prevention & control
Breast Neoplasms -- blood -- chemistry -- pathology
Collagen Type I -- metabolism
Confounding Factors (Epidemiology)
Disease Progression
Disease-Free Survival
Drug Administration Schedule
Female
Follow-Up Studies
Fractures, Spontaneous -- etiology -- prevention & control
Humans
Middle Aged
Odds Ratio
Osteogenesis -- drug effects
Postmenopause
Procollagen -- blood
Proportional Hazards Models
Receptors, Estrogen -- analysis
Sirolimus -- analogs & derivatives -- pharmacology -- therapeutic use
TOR Serine-Threonine Kinases -- antagonists & inhibitors
Treatment Failure
Treatment Outcome
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0027-8874
info:doi/10.1093/jnci/djt026
info:pii/djt026
info:scp/84877305137
info:pmid/23425564

Documents en relation

DI-fusion